title: Vitamin D transport proteins megalin and disabled-2 are expressed in prostate and colon epithelial cells and are induced and activated by all-trans-retinoic acid.
abstract: Megalin and disabled-2 (Dab2) are essential for uptake of the 25-hydroxycholecalciferol (25D3)-vitamin D binding protein (DBP) complex in tissues. In the kidney, this mechanism regulates serum 25D3 levels and production of 1,25-dihydroxycholecalciferol (1,25D3) by CYP27B1 for systemic use. Previously, we showed that mammary epithelial cells expressing CYP27B1 express megalin and Dab2 and internalize DBP by endocytosis, indicating 25D3 was accessible for conversion to 1,25D3 in extra-renal tissues. Moreover, induction of megalin and Dab2 (protein and mRNA abundance) by all-trans-retinoic acid (RA) enhanced DBP uptake. This suggests megalin and Dab2 play a central role in uptake of vitamin D and may predict actions of vitamin D in extra-renal tissues. Here, we characterized megalin and Dab2 expression and uptake of DBP in transformed human prostate and colon epithelial cells. Megalin and Dab2 were expressed in prostate and colon epithelial cells, which was markedly enhanced following treatment with RA. Furthermore, DBP uptake was stimulated by low-dose RA supplementation in LNCaP, PC-3, and Caco-2 cells. Taken together, these are the first studies to our knowledge that have demonstrated modulated expression of megalin and Dab2, as well as an association between increased expression of endocytic proteins with DBP uptake in prostate and colon cells.
authors.affiliation: Department of Food Science and Human Nutrition, Iowa State University, Ames, Iowa 50011, USA.
authors.forename: Shantel B
authors.initials: SB
authors.lastname: Ternes
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Rowling
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics* / Q000378:metabolism; D051017:Apoptosis Regulatory Proteins; D018938:Caco-2 Cells; D045744:Cell Line, Tumor; D003106:Colon / Q000166:cytology / Q000187:drug effects / Q000473:pathology; D004847:Epithelial Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D026561:Low Density Lipoprotein Receptor-Related Protein-2 / Q000235:genetics* / Q000378:metabolism; D008297:Male; D011467:Prostate / Q000166:cytology / Q000187:drug effects / Q000473:pathology; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D014212:Tretinoin / Q000494:pharmacology; D025521:Tumor Suppressor Proteins / Q000235:genetics* / Q000378:metabolism; D014807:Vitamin D / Q000493:pharmacokinetics*; D014809:Vitamin D-Binding Protein / Q000235:genetics / Q000378:metabolism
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D051017:Apoptosis Regulatory Proteins; C102885:DAB2 protein, human; D026561:Low Density Lipoprotein Receptor-Related Protein-2; D012333:RNA, Messenger; D025521:Tumor Suppressor Proteins; D014809:Vitamin D-Binding Protein; D014807:Vitamin D; D014212:Tretinoin
references.citation: J Natl Cancer Inst. 2012 May 2;104(9):690-9
references.pmid: 22499501
references.citation: Dermatoendocrinol. 2012 Apr 1;4(2):176-82
references.pmid: 22928074
references.citation: J Clin Endocrinol Metab. 2001 Feb;86(2):888-94
references.pmid: 11158062
references.citation: Cell. 1999 Feb 19;96(4):507-15
references.pmid: 10052453
references.citation: Am J Physiol Renal Physiol. 2005 Sep;289(3):F569-76
references.pmid: 15870384
references.citation: Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13895-900
references.pmid: 11717447
references.citation: J Natl Cancer Inst. 1992 Sep 2;84(17):1355-7
references.pmid: 1495105
references.citation: Urology. 1999 Jul;54(1):171-7
references.pmid: 10414747
references.citation: Cancer. 2003 Dec 15;98(12):2607-23
references.pmid: 14669280
references.citation: Oncogene. 2001 Apr 5;20(15):1860-72
references.pmid: 11313934
references.citation: J Nutr. 2008 Jul;138(7):1323-8
references.pmid: 18567755
references.citation: Oncologist. 1996;1(5):305-314
references.pmid: 10388008
references.citation: Breast Cancer Res. 2011 Jul 26;13(4):R74
references.pmid: 21791049
references.citation: Cancer Res. 2010 Mar 1;70(5):1835-44
references.pmid: 20160035
references.citation: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4400-6
references.pmid: 17671122
references.citation: Am J Clin Nutr. 2007 Jan;85(1):6-18
references.pmid: 17209171
references.citation: Ann Epidemiol. 2009 Jul;19(7):468-83
references.pmid: 19523595
references.citation: Development. 2002 Jul;129(13):3067-76
references.pmid: 12070083
references.citation: Autoimmun Rev. 2012 Dec;12(2):127-36
references.pmid: 22776787
references.citation: Am J Clin Nutr. 2007 Jun;85(6):1586-91
references.pmid: 17556697
references.citation: Nutr Rev. 2007 Aug;65(8 Pt 2):S91-5
references.pmid: 17867379
references.citation: Cancer Res. 2001 Apr 1;61(7):2852-6
references.pmid: 11306457
references.citation: J Clin Oncol. 2011 Oct 1;29(28):3775-82
references.pmid: 21876081
references.citation: Endocrinology. 2004 Dec;145(12):5840-6
references.pmid: 15319350
references.citation: Oncogene. 1999 May 20;18(20):3104-13
references.pmid: 10340382
references.citation: Lancet. 1985 Feb 9;1(8424):307-9
references.pmid: 2857364
references.citation: Dermatoendocrinol. 2011 Jul;3(3):199-204
references.pmid: 22110780
references.citation: World J Gastroenterol. 2006 Oct 7;12(37):6041-5
references.pmid: 17009406
references.citation: J Nutr. 2006 Nov;136(11):2754-9
references.pmid: 17056796
references.citation: Trends Cardiovasc Med. 2001 Jan;11(1):26-31
references.pmid: 11413049
references.citation: Eur Arch Otorhinolaryngol. 2011 Aug;268(8):1201-1204
references.pmid: 21221617
references.citation: Cancer Lett. 1990 Dec 3;55(2):149-52
references.pmid: 2265414
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1850-60
references.pmid: 21784952
references.citation: Anticancer Res. 2008 Jul-Aug;28(4A):2009-13
references.pmid: 18649740
references.citation: Cancer Causes Control. 2012 Feb;23(2):363-70
references.pmid: 22193397
references.citation: Cancer Epidemiol Biomarkers Prev. 1999 May;8(5):399-406
references.pmid: 10350434
references.citation: BMC Cancer. 2006 Nov 10;6:264
references.pmid: 17096841
references.citation: J Am Soc Nephrol. 1999 Oct;10(10):2224-36
references.pmid: 10505701
references.citation: Br J Cancer. 2009 Sep 15;101(6):916-23
references.pmid: 19690551
references.citation: Int J Cancer. 2009 Feb 15;124(4):979-86
references.pmid: 19035445
references.citation: Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):82-91
references.pmid: 22086883
references.citation: J Nutr. 2003 Jul;133(7 Suppl):2425S-2433S
references.pmid: 12840219
references.citation: Am J Physiol. 1996 Oct;271(4 Pt 2):F900-7
references.pmid: 8898021
references.citation: J Biol Chem. 2000 Mar 10;275(10):7125-37
references.pmid: 10702280
references.citation: Br J Cancer. 1997;76(8):1017-20
references.pmid: 9376260
references.citation: Anticancer Res. 2012 Jan;32(1):223-36
references.pmid: 22213311
references.citation: Circ Cardiovasc Qual Outcomes. 2012 Nov;5(6):819-29
references.pmid: 23149428
references.citation: Cancer Causes Control. 2010 Oct;21(10):1701-9
references.pmid: 20552265
references.citation: Endocr Relat Cancer. 2002 Mar;9(1):45-59
references.pmid: 11914182
references.citation: Dermatoendocrinol. 2012 Apr 1;4(2):198-202
references.pmid: 22928077
references.citation: Eur J Clin Nutr. 2011 Sep;65(9):1005-15
references.pmid: 21731035
references.citation: Adv Exp Med Biol. 1995;375:45-52
references.pmid: 7645427
references.citation: J Nutr. 2006 Apr;136(4):887-92
references.pmid: 16549446
references.citation: J Photochem Photobiol B. 2010 Nov 3;101(2):130-6
references.pmid: 20570169